Just eight days after AstraZeneca (AZN) announced the expansion of clinical trials of its AZD1222 vaccine against coronavirus into randomized, double-blind, placebo-controlled Phase 3 in the U.S., disaster struck. Medical journal Stat reported (and this report was later confirmed by AstraZeneca itself) “a suspected serious adverse reaction in a participant in the United Kingdom” Phase III trial conducted by AstraZeneca and the University of Oxford.AstraZeneca gave no further details on the adverse reaction in question. Indeed, in reporting on the news, J.P. Morgan analyst Cory Kasimov characterized AstraZeneca’s brief comments on Stat’s article as containing “zero details” on precisely what …read more
Source:: Yahoo Finance
